Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMVT Immunovant, Inc.

Not Yet Opened 11-04 16:00:00 EST

29.42

+0.03

+0.10%

盘后29.42

+0.000.00%

17:29 EST

High30.00	Low28.28	Vol849.96K
Open29.50	D1 Closing29.39	Amplitude5.85%
Mkt Cap4.31B	Tradable Cap1.92B	Total Shares146.37M
T/O24.86M	T/O Rate1.30%	Tradable Shares65.25M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"IMVT","market":"US","secType":"STK","nameCN":"Immunovant, Inc.","latestPrice":29.42,"timestamp":1730754000000,"preClose":29.39,"halted":0,"volume":849964,"hourTrading":{"tag":"盘后","latestPrice":29.42,"preClose":29.42,"latestTime":"17:29 EST","volume":16544,"amount":486724.8804,"timestamp":1730759340287},"delay":0,"floatShares":65253941,"shares":146367374,"eps":-1.91941,"marketStatus":"Not Yet Opened","change":0.03,"latestTime":"11-04 16:00:00 EST","open":29.5,"high":30,"low":28.28,"amount":24858885.208504,"amplitude":0.058523,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.91941,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1730797200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":29.39,"preHourTrading":{"tag":"盘前","latestPrice":29.24,"preClose":29.39,"latestTime":"09:29 EST","volume":218,"amount":6397.110156,"timestamp":1730730596689},"postHourTrading":{"tag":"盘后","latestPrice":29.42,"preClose":29.42,"latestTime":"17:29 EST","volume":16544,"amount":486724.8804,"timestamp":1730759340287},"volumeRatio":1.596554,"impliedVol":0.4009,"impliedVolPercentile":0.1195},"requestUrl":"/m/hq/s/IMVT","defaultTab":"news","newsList":[{"id":"2479147132","title":"Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2479147132","media":"THOMSON REUTERS","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479147132?lang=en_us&edition=fundamental","pubTime":"2024-10-29 18:30","pubTimestamp":1730197800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nTUA2DN8MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMVT","BK4588","BK4585"],"gpt_icon":0},{"id":"2475340676","title":"Immunovant: Switching Lead Candidates Increases Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2475340676","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475340676?lang=en_us&edition=fundamental","pubTime":"2024-10-15 02:55","pubTimestamp":1728932134,"startTime":"0","endTime":"0","summary":"Immunovant, Inc. switched focus from batoclimab to IMVT-1402, an anti-FcRn monoclonal antibody, to avoid cholesterol-related side effects.IMVT-1402 shows promise in reducing IgG antibodies without inc","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1253986380/image_1253986380.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1253986380/image_1253986380.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4726699-immunovant-switching-lead-candidates-increases-risk","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4585","BK4139","IMVT","BK4588"],"gpt_icon":0},{"id":"2474244861","title":"Oppenheimer Adjusts Immunovant Price Target to $53 From $47, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2474244861","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474244861?lang=en_us&edition=fundamental","pubTime":"2024-10-09 20:14","pubTimestamp":1728476062,"startTime":"0","endTime":"0","summary":"Immunovant Inc (IMVT) has an average rating of Buy and price targets ranging from $41 to $60, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic research fr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMVT","OPY"],"gpt_icon":0},{"id":"2474924162","title":"Immunovant, Inc. : Oppenheimer Raises Target Price to $53 From $47","url":"https://stock-news.laohu8.com/highlight/detail?id=2474924162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474924162?lang=en_us&edition=fundamental","pubTime":"2024-10-09 20:03","pubTimestamp":1728475409,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241009:nAZN2DKSA9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMVT","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2472379326","title":"Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?","url":"https://stock-news.laohu8.com/highlight/detail?id=2472379326","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472379326?lang=en_us&edition=fundamental","pubTime":"2024-10-01 21:58","pubTimestamp":1727791105,"startTime":"0","endTime":"0","summary":"We recently compiled a list of 10 Worst Performing Stocks to Buy on the Dip. In this article, we will look at where Immunovant, Inc.  ranks among the worst performing stocks to buy on the dip.Capital markets demonstrated increased volatility starting in August 2024 and continuing in September 2024. That being said, strong rallies followed numerous negative performance days. Therefore, these movements have helped keep the stocks moving in an overall positive direction. Market experts believe this is a great time to invest in equities. For those having money in cash, the current juncture provides an opportunity to put capital to work in the longer-term assets.The initial seven months of 2024 saw the broader market move forward, with only modest interruption or volatility. After a tough August start, the stocks recovered quickly, and the broader markets again ended the month in positive territory","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZyvYqvKxNpBWlHwzdONqtQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/936769d778c202b5bc0f6633f10948f7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZyvYqvKxNpBWlHwzdONqtQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/936769d778c202b5bc0f6633f10948f7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunovant-inc-imvt-worst-performing-135825868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","ESmain","SSO","SPXU","PSQ","OEF","MNQmain","US912797HE00.BOND","BK4585","US7Y.BOND","UPRO","US12M.BOND","BK4516","SH","BK4504","BK4566","SPY","QID","BK4559","QLD","US912797GW17.BOND",".SPX","BK4534","BK4588","US5Y.BOND","SQQQ","US2Y.BOND","US3Y.BOND","NQmain","IMVT","US6M.BOND","BK4139","US30Y.BOND","TQQQ","BK4187","SDS","GD","US10Y.BOND","BK4581","OEX","BK4550","IVV","LU0170899867.USD","VOO"],"gpt_icon":1},{"id":"2471387003","title":"Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2471387003","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471387003?lang=en_us&edition=fundamental","pubTime":"2024-09-30 23:12","pubTimestamp":1727709143,"startTime":"0","endTime":"0","summary":"We recently made a list of the 10 Best NASDAQ Stocks Under $50 to Buy. In this piece, we will look at where Roivant Sciences Ltd.  ranks among the best NASDAQ stocks under $50 to buy.The close of 2024’s third quarter is seeing Wall Street rejoice as the Federal Reserve finally delivers its highly awaited interest rate cut. The central bank decided to cut rates by 50 basis points, and while the immediate aftermath saw stocks close lower, the next day was the complete opposite. On the day after the interest rate cut, markets soared as investors digested the latest data set.Within these, the top four stocks account for 40% of the ETF, and as the lowest of these top four stocks’ returns is still higher than the broader index’s year to date performance, it’s clear that outperformance among the largest c","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GObHJEZCO1RRRMQhXa4VOA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/ed38af0a5ffc625b6778b4424aec06c7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GObHJEZCO1RRRMQhXa4VOA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/ed38af0a5ffc625b6778b4424aec06c7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roivant-sciences-ltd-nasdaq-roiv-151223852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4112","BK4011","BK4139","NDAQ","SMID","IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","IMVT",".IXIC","NQmain","BK4007","LU2210149790.SGD","TQQQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","SQQQ","QLD","IE00B3QW5Z07.USD","MNQmain","ROIV","QID","BK4585","PSQ"],"gpt_icon":1},{"id":"2471877138","title":"Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2471877138","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471877138?lang=en_us&edition=fundamental","pubTime":"2024-09-30 18:23","pubTimestamp":1727691780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 30, 2024 06:23 ET (10:23 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT"],"gpt_icon":0},{"id":"2470265332","title":"Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2470265332","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470265332?lang=en_us&edition=fundamental","pubTime":"2024-09-25 22:25","pubTimestamp":1727274340,"startTime":"0","endTime":"0","summary":"Argenx stock surged Wednesday after Amgen presented \"underwhelming\" results for a potential competitor to Vyvgart in an autoimmune disease.","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2023/10/Stock-argenx-01-shutt-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2023/10/Stock-argenx-01-shutt-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/argenx-stock-amgen-stock-uplizna/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["IE0009355771.USD","LU0289739699.SGD","ARGX","BK4588","AMGN","LU0058720904.USD","IE00BFTCPJ56.SGD","BK4566","LU1571399168.USD","BK4534","KYTX","LU2242652126.USD","BK4581","IE00B2B36J28.USD","BK4533","LU0320765992.SGD","RNAC","LU0122379950.USD","IE0002141913.USD","BK4585","LU0889565916.HKD","BK4139","LU2242646821.SGD","LU2112291526.USD","LU0868494617.USD","IMVT","IE00BJT1NW94.SGD","LU1023059063.AUD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU1983299246.USD","LU0109394709.USD","SG9999001440.SGD","LU1057294990.SGD","LU1061106388.HKD","BK4505"],"gpt_icon":1},{"id":"2467978039","title":"Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2467978039","media":"Zacks","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467978039?lang=en_us&edition=fundamental","pubTime":"2024-09-13 00:49","pubTimestamp":1726159740,"startTime":"0","endTime":"0","summary":"It was a busy week for the biotech sector, with a lot of important data readouts and regulatory updates. Among these, Terns Pharmaceuticals TERN and Summit Therapeutics SMMT surged after reporting positive data on important pipeline candidates.Terns Surges on Obesity Drug Data: Terns Pharmaceuticals, a clinical-stage company, announced positive top-line data from its phase I single and multiple-ascending dose  obesity study. Its shares soared on the news, given the potential of the obesity market. The phase I study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of its investigational, oral, small-molecule GLP-1R agonist, TERN-601, dosed once daily in healthy adults with obesity or overweight.The maximum placebo-adjusted mean weight loss of 4.9% was observed at the highest dose of TERN-601 , administered once daily. It was also observed that 67% of the patients treated with the candidate, lost 5% or more of their baseline body weight at the 740 mg dosage stren","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QieiOVP5CdM1cfxTnlcVfQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QieiOVP5CdM1cfxTnlcVfQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-tern-smmt-164900010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RLAY","LU1061106388.HKD","LU1917777945.USD","LU1066051498.USD","BK4213","IE00BLSP4239.USD","LU1057294990.SGD","PR","MRK","IE00BJJMRZ35.SGD","LU0265550359.USD","BK4563","BK4585","BK4533","BK4007","BK4516","SMMT","LU0122379950.USD","LU1934455863.HKD","IE00BJT1NW94.SGD","PFS","LU1116320737.USD","LU1023059063.AUD","LU1066053197.SGD","BK4588","BK4532","LU1066051225.USD","LU1585245621.USD","GSK.UK","LU1093756325.SGD","IE0009355771.USD","IE00BBT3K403.USD","BK4195","IMVT","LU0058720904.USD","BK4139","IE0002141913.USD","TERN","GSK","LU0006306889.USD","IE00BFTCPJ56.SGD","MBC","IE000M9KFDE8.USD","LU0203345920.USD","BK4550","LU0211331839.USD","LU0203347892.USD","IE00B1BXHZ80.USD","LU0965509283.SGD","LU1066051811.HKD"],"gpt_icon":1},{"id":"2466369492","title":"Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way","url":"https://stock-news.laohu8.com/highlight/detail?id=2466369492","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466369492?lang=en_us&edition=fundamental","pubTime":"2024-09-11 05:09","pubTimestamp":1726002577,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics, Inc. reported that the primary endpoint was met for the phase 3 THRIVE study, using veligrotug for the treatment of patients with active thyroid eye disease.Data release for THR","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154029246/image_2154029246.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154029246/image_2154029246.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4720284-viridian-active-ted-data-signifies-next-round-of-positive-data-on-the-way","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IE00B4R5TH58.HKD","LU1059921491.USD","LU0882574055.USD","ARGX","LU1066053197.SGD","BK4139","BK4550","LU0058720904.USD","LU0122379950.USD","LU0109394709.USD","LU0792757196.USD","VRDN","IE00BJT1NW94.SGD","LU2242652126.USD","IMVT","BK4532","LU1066051225.USD","BK4533","JNJ","BK4568","LU1221951129.SGD","LU1506573853.SGD","IE0002141913.USD","LU1066051811.HKD","IE00B2B36J28.USD","LU0234572021.USD","LU1066051498.USD","LU1162221912.USD","AMGN","LU0345770308.USD","IE00BGHQF631.EUR","IE0034235303.USD","LU1261432733.SGD","UCBJY","BK4566","LU0795875169.SGD","LU2112291526.USD","LU1585245621.USD","LU0345770993.USD","BK4504","LU1032955483.USD","LU1057294990.SGD","BK4505","IE0002270589.USD","LU0640476718.USD","IE00BDGV0183.EUR","THAC","BK4585","LU0912757837.SGD","LU1244550494.USD"],"gpt_icon":0},{"id":"2466436146","title":"Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2466436146","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466436146?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:25","pubTimestamp":1725967500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 10, 2024 07:25 ET (11:25 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT"],"gpt_icon":0},{"id":"2466846784","title":"Immunovant Inc : Citigroup Raises Target Price to $60 From $51","url":"https://stock-news.laohu8.com/highlight/detail?id=2466846784","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466846784?lang=en_us&edition=fundamental","pubTime":"2024-09-10 17:36","pubTimestamp":1725960993,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240910:nFWN3KS0DP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMVT","BK4585","BK4588"],"gpt_icon":0},{"id":"2466149367","title":"Immunovant stock falls 8% amid Graves' disease program update","url":"https://stock-news.laohu8.com/highlight/detail?id=2466149367","media":"seekingalpha","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466149367?lang=en_us&edition=fundamental","pubTime":"2024-09-10 05:18","pubTimestamp":1725916718,"startTime":"0","endTime":"0","summary":"Immunovant  stock fell 8% Monday after it reported data from a Phase 2a study of batoclimab in the treatment of Graves’ disease, adding the FDA has cleared it to begin a pivotal trial of its drug candidate IMVT-1402 for the same disease.  The biotech company said the Phase 2a study showed high dose batoclimab achieved a 76% response rate in patients who were uncontrolled on anti-thyroid drugs at week 12. Immunovant also said the FDA has cleared its Investigational New Drug application for a pivotal trial of IMVT-1402 in the treatment of Graves’ disease. The study is expected to begin by the end of the year, according to a statement. Citi said in a note on Monday that Immunovant remains one of its top picks, calling the Phase 2 data encouraging. The investment bank raised its price target to $60 from $51. Immunovant is a subsidiary of Roivant .","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/514725908/image_514725908.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/514725908/image_514725908.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4148174-immunovant-stock-falls-amid-graves-disease-program-update","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["NQmain","BK4139","SQQQ","BK4588","IMVT","ROIV","QID","BK4007","QLD",".IXIC","TQQQ","PSQ","MNQmain","BK4585"],"gpt_icon":1},{"id":"2466119908","title":"Citigroup Raises Immunovant's Price Target to $60 From $51, Buy Rating Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2466119908","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466119908?lang=en_us&edition=fundamental","pubTime":"2024-09-10 02:23","pubTimestamp":1725906220,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT) has an average buy rating and price target range of $41 to $57, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic research from major ban","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMVT"],"gpt_icon":0},{"id":"2466113429","title":"What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2466113429","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466113429?lang=en_us&edition=fundamental","pubTime":"2024-09-10 00:54","pubTimestamp":1725900853,"startTime":"0","endTime":"0","summary":"Monday, Immunovant,Inc.  reported results from the Phase 2a trial of batoclimab in Graves’ Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone.Immunovant is a member of theRoivant Sciences Ltd. family of companies.Also Read: Vivek Ramaswamy-Founded Roivant’s Anti-Inflammatory Drug Aces Mid-Stage Study.As previously disclosed, the batoclimab phase 2a trial in uncontrolled Graves’ Disease enrolled patients who were hyperthyroid despite antithyroid drugs  therapy.Participants in the trial received 12 weeks of high-dose batoclimab, 680 mg weekly by subcutaneous injection  followed by 12 weeks of lower-dose batoclimab, 340 mg weekly SC.At the end of the first 12 weeks, participants experienced a mean IgG reduction of 77%, leading to a 76% Response rate.In addition, by the end of 12 weeks of higher dose batoclimab, 56% achieved an ATD-Free Response.Despite benefiting from a lower starting IgG level after 12 weeks of 680mg th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/l7qwqxNzpBSZJRbb83.Byg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/2666d1db27f3612d82e18134e270e74c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/l7qwqxNzpBSZJRbb83.Byg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/2666d1db27f3612d82e18134e270e74c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/whats-going-vivek-ramaswamy-founded-165413401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4139","IMVT","ROIV","BK4585","BK4007"],"gpt_icon":0},{"id":"2466499197","title":"LifeSci Capital Sticks to Its Buy Rating for Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2466499197","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466499197?lang=en_us&edition=fundamental","pubTime":"2024-09-10 00:05","pubTimestamp":1725897943,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant (IMVT – Research Report) today and set a price target of $51.00. The comp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-sticks-to-its-buy-rating-for-immunovant-imvt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-sticks-to-its-buy-rating-for-immunovant-imvt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"gpt_icon":0},{"id":"2466193492","title":"IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2466193492","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466193492?lang=en_us&edition=fundamental","pubTime":"2024-09-09 20:35","pubTimestamp":1725885300,"startTime":"0","endTime":"0","summary":"Shares of Immunovant IMVT are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being developed for Graves’ Disease .IMVT’s Batoclimab Shows Superior Efficacy in GD Patients. The enrolled patient population of the phase IIa study of batoclimab comprised uncontrolled GD patients who were hyperthyroid despite anti-thyroid drugs  therapy.Patients were then treated with the high batoclimab dose, 680 mg weekly subcutaneous injection , for 12 weeks, followed by another 12 weeks of lower batoclimab dose, 340 mg weekly SC.Apart from the GD study, separate mid to late-stage studies are also currently ongoing, evaluating batoclimab for the treatment of other autoimmune indications, like Myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and thyroid eye disease. Subject to positive data from these studies, Immunovant plans to study IMVT-1402 for each of the above ind","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imvt-stock-upbeat-data-graves-123500299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4534","BK4535","BK4548","BK4585","ILMN","BK4566","BK4550","BK4187","BK4516","BK4121","BK4588","BK4139","KRYS","GD","IMVT","LU0170899867.USD","FULC"],"gpt_icon":0},{"id":"2466816370","title":"Immunovant's Graves' Disease Drug Shows Improved Efficacy at Higher Doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2466816370","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466816370?lang=en_us&edition=fundamental","pubTime":"2024-09-09 19:09","pubTimestamp":1725880151,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4139","BK4585","BK4588","IMVT"],"gpt_icon":0},{"id":"2466163279","title":"Immunovant's Graves' Disease Drug Shows Improved Efficacy at Higher Doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2466163279","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466163279?lang=en_us&edition=fundamental","pubTime":"2024-09-09 19:09","pubTimestamp":1725880151,"startTime":"0","endTime":"0","summary":"Immunovant said on Monday that high doses of its experimental drug batoclimab to treat Graves' Disease significantly reduced IgG levels and improved patient responses compared to lower doses in a phase 2 study.The study showed that a 680 mg weekly dose led to a 77% reduction in IgG and a 76% response rate, while the 340 mg dose resulted in a 65% IgG reduction and a 68% response rate.The company plans to commence a pivotal trial of IMVT-1402 in Graves' Disease by December 31, following the U.S. Food & Drug Administration alignment and Investigational New Drug Application clearance.Price: 34.50, Change: +0.47, Percent Change: +1.38","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4588","IMVT","BK4585"],"gpt_icon":0},{"id":"2466316870","title":"Roivant Provides Update on Graves’ Disease Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2466316870","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466316870?lang=en_us&edition=fundamental","pubTime":"2024-09-09 19:00","pubTimestamp":1725879601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240909:nTUA29GKNV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4588","IMVT","BK4007","ROIV","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunovant.com","stockEarnings":[{"period":"1week","weight":-0.0177},{"period":"1month","weight":-0.0357},{"period":"3month","weight":0.0564},{"period":"6month","weight":-0.0114},{"period":"1year","weight":-0.1345},{"period":"ytd","weight":-0.3017}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0913},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.3108},{"period":"ytd","weight":0.1988}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.094855},{"month":2,"riseRate":0,"avgChangeRate":-0.169332},{"month":3,"riseRate":0.2,"avgChangeRate":-0.041053},{"month":4,"riseRate":0.4,"avgChangeRate":-0.020694},{"month":5,"riseRate":0.4,"avgChangeRate":0.099229},{"month":6,"riseRate":0.2,"avgChangeRate":-0.098266},{"month":7,"riseRate":0.5,"avgChangeRate":0.046357},{"month":8,"riseRate":0.666667,"avgChangeRate":0.108139},{"month":9,"riseRate":0.833333,"avgChangeRate":0.124733},{"month":10,"riseRate":0.666667,"avgChangeRate":0.178851},{"month":11,"riseRate":0.833333,"avgChangeRate":0.078815},{"month":12,"riseRate":0.8,"avgChangeRate":0.198952}],"exchange":"NASDAQ","name":"Immunovant, Inc.","nameEN":"Immunovant, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunovant, Inc.,IMVT,Immunovant, Inc.股票,Immunovant, Inc.股票老虎,Immunovant, Inc.股票老虎国际,Immunovant, Inc.行情,Immunovant, Inc.股票行情,Immunovant, Inc.股价,Immunovant, Inc.股市,Immunovant, Inc.股票价格,Immunovant, Inc.股票交易,Immunovant, Inc.股票购买,Immunovant, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}